Active Ingredient History
Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, a severe form of arthritis in children, and COVID‑19. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. Tocilizumab was jointly developed by Osaka University and Chugai, and was licensed in 2003 by Hoffmann-La Roche. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Chest Syndrome (Phase 2)
Adalimumab (Phase 4)
Adamantinoma (Phase 2)
Adrenal Cortex Hormones (Phase 4)
Allografts (Phase 2)
Amyotrophic Lateral Sclerosis (Phase 2)
Anemia, Sickle Cell (Phase 2)
Aneurysm (Phase 2)
Antigens, CD19 (Phase 1)
Ascites (Phase 1)
Astrocytoma (Phase 2)
Autoimmune Diseases (Phase 2)
Behcet Syndrome (Phase 2)
Biliary Tract Neoplasms (Phase 1)
Biological Therapy (Phase 2)
Biomarkers (Phase 3)
Bone Marrow Transplantation (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Neuroendocrine (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 1/Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Castleman Disease (Phase 2)
Cogan Syndrome (Phase 2)
Colorectal Neoplasms (Phase 1/Phase 2)
Coronary Artery Disease (Phase 3)
Coronary Disease (Phase 2)
Coronaviridae Infections (Phase 3)
Coronavirus (Phase 3)
Coronavirus Infections (Phase 3)
COVID-19 (Phase 4)
Craniopharyngioma (Phase 2)
Cryoglobulinemia (Phase 2)
Cytokine Release Syndrome (Phase 4)
Depressive Disorder, Major (Phase 2)
Dermatomyositis (Phase 2)
Diabetes Mellitus (Phase 3)
Diabetes Mellitus, Type 1 (Phase 2)
Drug Combinations (Phase 4)
Drugs, Investigational (Phase 4)
Epilepsy (Phase 3)
Erdheim-Chester Disease (Phase 2)
Esophageal Neoplasms (Phase 2)
Familial Mediterranean Fever (Phase 2)
Fever (Phase 2)
Fibrous Dysplasia of Bone (Phase 2)
Giant Cell Arteritis (Phase 4)
Glioblastoma (Phase 2)
Graft Rejection (Phase 4)
Graft vs Host Disease (Phase 2)
Granulomatosis with Polyangiitis (Phase 2)
Granulomatous Disease, Chronic (Phase 1/Phase 2)
Graves Ophthalmopathy (Phase 3)
Healthy Volunteers (Phase 4)
Heart Arrest (Phase 2)
Heart Transplantation (Phase 2)
Hematologic Neoplasms (Phase 2)
Hematoma, Subdural, Chronic (Phase 1/Phase 2)
Hematopoietic Stem Cell Transplantation (Phase 2)
HIV Infections (Phase 1/Phase 2)
Hodgkin Disease (Phase 2)
IgA Vasculitis (Phase 2)
Inflammation (Phase 3)
Intensive Care Units (Phase 3)
Interleukin-6 (Phase 3)
Janus Kinase Inhibitors (Phase 3)
Kidney Failure, Chronic (Phase 3)
Kidney Transplantation (Phase 2)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Liver Neoplasms (Phase 1/Phase 2)
Lung Diseases, Interstitial (Phase 2/Phase 3)
Lung Neoplasms (Phase 2)
Lung Transplantation (Phase 2)
Lupus Erythematosus, Systemic (Phase 1)
Lymphohistiocytosis, Hemophagocytic (Phase 2)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 1)
Lymphoma, Follicular (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Immunoblastic (Phase 1)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 3)
Macrophage Activation Syndrome (Phase 2)
Macular Edema (Phase 2)
Melanoma (Phase 2)
Methotrexate (Phase 4)
Motor Neuron Disease (Phase 2)
Multiple Myeloma (Phase 4)
Myasthenia Gravis (Phase 2/Phase 3)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Myocardial Infarction (Phase 2)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 3)
Neuromyelitis Optica (Phase 2/Phase 3)
Nidovirales Infections (Phase 3)
Non-ST Elevated Myocardial Infarction (Phase 2)
Optic Neuropathy, Ischemic (Phase 2)
Osteoarthritis (Phase 3)
Out-of-Hospital Cardiac Arrest (Phase 2)
Ovarian Neoplasms (Phase 1/Phase 2)
Pancreatic Neoplasms (Phase 2)
Pharmacokinetics (Phase 1)
Pleural Effusion, Malignant (Phase 1)
Pneumonia (Phase 4)
Pneumonia, Viral (Phase 2)
Polyarteritis Nodosa (Phase 2)
Polychondritis, Relapsing (Phase 2)
Polymyalgia Rheumatica (Phase 3)
Polymyositis (Phase 2)
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)
Psychotic Disorders (Phase 4)
Pulmonary Arterial Hypertension (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 3)
Respiratory Distress Syndrome (Phase 2)
Respiratory Insufficiency (Phase 2)
Respiratory Tract Diseases (Phase 3)
Respiratory Tract Infections (Phase 3)
Retroperitoneal Fibrosis (Phase 4)
RNA Virus Infections (Phase 3)
SARS-CoV-2 (Phase 3)
Schizophrenia (Phase 4)
Schnitzler Syndrome (Phase 2)
Scleroderma, Systemic (Phase 3)
Severe Acute Respiratory Syndrome (Phase 3)
Shock, Cardiogenic (Phase 2)
Sjogren's Syndrome (Phase 2/Phase 3)
Small Cell Lung Carcinoma (Phase 1)
Spondylitis, Ankylosing (Phase 3)
Still's Disease, Adult-Onset (Phase 2)
Stroke (Phase 3)
Systemic Inflammatory Response Syndrome (Phase 2)
Takayasu Arteritis (Phase 4)
Therapeutics (Phase 4)
Triple Negative Breast Neoplasms (Phase 2)
Ultrasonography (Phase 3)
Ureteral Neoplasms (Phase 2)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uveitis (Phase 2)
Uveitis, Intermediate (Phase 1/Phase 2)
Uveitis, Posterior (Phase 1/Phase 2)
Vascular Diseases (Phase 3)
Vasculitis (Phase 2)
Virus Diseases (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
